Alfasigma

#PharmaP (Berlin, April 14-15) was an important and prestigious opportunity to present Morpho, our specialty Contract Development and Manufacturing Organisation (CDMO), providing globally end-to-end pharmaceutical and nutraceutical solutions . With a strong international presence and over 60 years of experience, Morpho is committed to driving innovation and offering tailored solutions to meet the unique needs of our partners worldwide  The PharmaP event, a key gathering of over 300 industry leaders, was the perfect platform to exchange insights and highlight how Morpho’s know how and advanced technologies ensure excellence and innovation at every stage of the development and manufacturing process. Whether through value-added development or cutting-edge manufacturing technologies, Morpho is today a strategic partner,evolving from a CMO to a specialty CDMO, fully equipped to support our clients across every stage of pharmaceutical development and manufacturing. #PharmaP #SpecialtyCDMO #Alfasigma #Morpho #PharmaceuticalwithPassion 

On this #WorldHealthDay, we firmly stand with the global community to support better healthcare for everyone across the world. “Healthy beginnings, hopeful futures” is the title of this year’s campaign, urging us to remember that the health of mothers and babies is the foundation of healthy families and communities, helping ensure hopeful futures for us all.   Let’s work together to make it possible!   #WorldHealthDay #HopefulFuture #PharmaceuticalsWithPassion

2024 marked a historic milestone for Alfasigma. Today, we published our full-year financial results, showcasing record-breaking growth: €1.87 billion in revenue (a 37% YoY increase) and a 23% rise in adjusted EBITDA to €427 million. This performance reflects the strength of our strategic transformation, fuelled by successful acquisitions and the strong performance of our legacy brands. With assets recently acquired which reinforce our rare disease and specialty care offering, we're accelerating towards our ambition to become a global innovative healthcare company focused on GI and hepatology. You can read more here: https://lnkd.in/d-QyfvQM #Alfasigma #RareDisease #SpecialtyCare #FinancialResults #StrategicGrowth

Gender equality does not happen in a vacuum! Acceleration requires collaboration, determination, and collective action. Around the world, organizations and individuals are uniting to drive progress in key areas like women’s economic empowerment, leadership, and representation in STEM. Globally, women hold just 31.7% of senior leadership roles – and that’s not good enough. At Alfasigma, we’ve surpassed this number, but we’re still eager to accelerate our efforts and have more women contribute to our business. An inclusive environment only makes us better! #InternationalWomensDay #AccelerateAction #PharmaceuticalWithPassion   Source: World Economic Forum, Global Gender Gap 2024, Insight Report June 2024

Today is #RareDiseaseDay! Every rare disease tells a unique story, more than you can imagine. A disease is considered rare when it affects fewer than 1 in 2,000 people, but for those living with one, rarity does not mean invisibility. Patients with rare diseases face multiple challenges every day: 💡 Delayed diagnosis due to limited scientific knowledge and complex symptoms ⚕️ Difficult access to treatment and care, leading to inequalities 🔄 Misdiagnosis, as many rare diseases share symptoms with more common conditions 🌍 The need for global commitment to connect experts and drive innovation At Alfasigma, we believe that no disease is too rare to deserve attention. We are committed to addressing patients’ needs and innovating to create life-changing solutions. Together, we can do more. #PharmaceuticalsWithPassion #RareDiseaseDay2025 #RareDiseases Source: www.rarediseaseday.org

Wrapping Up an Inspiring ECCO 2025!  As ECCO 2025 comes to an end, we reflect on the insightful scientific discussions and meaningful exchanges that took place during the event, bringing us all together around the shared goal of improving the lives of people with IBD and gastrointestinal disorders. The congress was a valuable opportunity to strengthen collaboration within the scientific, healthcare and patient communities. #PharmaceuticalsWithPassion #ECCO2025 #UlcerativeColitis #IBD 

Alfasigma is proud to have supported #Rust2Dakar 2024, the charity rally organized by the humanitarian association Tavolo8 ODV to raise awareness and funds for cooperation projects benefiting the most vulnerable groups in West Africa. Marina Golinelli, Deputy Chairman of Alfasigma, took part in the rally as a member of the RustyPenguins team. This 6,023 km journey saw participants raise donations and helped spread the word about the projects and initiatives in West Africa by sharing updates on social media. At the end of this journey, the vehicles were donated to local communities in Africa to support Tavolo8’s humanitarian projects. Our car, "Sally," will continue to make important journeys at the Catholic mission of Suzana in Guinea-Bissau, enabling them to provide essential medical care to women and families in remote local communities. This initiative reflects our belief that even a small gesture can make a lasting impact by creating a strong, supportive, and collaborative community. #PharmaceuticalsWithPassion #WeAreAlfasigma

We are excited to be part of the 20th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Berlin from February 19–22. Our participation in the congress and the new findings that will be presented, underline Alfasigma’s commitment to advancing care and improving the quality of life for people with gastrointestinal diseases such as Ulcerative Colitis. Alfasigma will also host a Satellite Symposium: 🗓 February 20, 19:00–20:00 📍 Room A4 💡 Topic: "Moderately Active UC in the Spotlight" https://lnkd.in/dqshTkf7 #PharmaceuticalsWithPassion #ECCO2025 #UlcerativeColitis #IBD

This week, we hosted our first Alfasigma Global Connect, live from the Opificio Golinelli, with thousands of colleagues joining us from around the Alfasigma world 🌍. It was a unique opportunity to connect as one team, focused on our shared priorities for 2025. 2024 was a truly transformational year – we achieved and learned a lot and increased our presence across the world. The strategy to continue our growth journey in 2025 is clear. Driven by passion for innovation, our teams are building the future by working side by side to provide better health and a better quality of life for people in three main therapeutic areas: gastroenterology, vascular, and rheumatology. The journey continues – and it’s us who Define the Future for Alfasigma, together 🚀. #PharmaceuticalsWithPassion #WeAreAlfasigma

As we approach the festive season and the end of another year, we want to thank all of you: our partners, colleagues, and community, for being part of our journey. We are excited to continue this journey with you in the year ahead. From all of us, warm wishes for joyful celebrations and an inspiring start to 2025! #PharmaceuticalsWithPassion #AlfasigmaHealthHub